Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials reg...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Med Hypotheses
Autori principali: Kavanagh, Oisín, Marie Healy, Anne, Dayton, Francis, Robinson, Shane, O'Reilly, Niall J., Mahoney, Brian, Arthur, Aisling, Walker, Gavin, Farragher, John P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier Ltd. 2020
Soggetti:
Letter to Editors
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://ncbi.nlm.nih.gov/pubmed/33017904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mehy.2020.110110
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi